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value of such observational datasets, relative to the con-
struction or use of RCT study designs. METHODS: A
systematic review of a health economics literature data-
base (HEED) was conducted to explore the use of obser-
vational and RCT data in applied pharmacoeconomic
evaluations in the UK (1990–1999). A comparative anal-
ysis of longitudinal datasets (containing resource use and
outcomes data) developed in the UK (e.g. DIN-LINK,
GPRD) was undertaken with an assessment of the poten-
tial analytical approaches (multivariate techniques, cross-
design synthesis) and methodological and practical con-
siderations. RESULTS: A total of 71 studies were identi-
fied, 59 CEAs only, 6 CUAs only and 6 where both CEAs
and CUAs were conducted. The table presents the type of
data used in these studies for the three core data items of
a pharmacoeconomic evaluation. RCT data represented
the majority source for all three items, in particular for
clinical event and disease outcome data. Observational
data sources were more frequently used to provide re-
source use consequence data. None of the reviewed stud-
ies made use of any existing prospective or retrospective
database. CONCLUSIONS: Regardless of the system of
health care, there is an obvious and universal need for re-
liable data on the effectiveness and costs of clinical inter-
ventions. Observational datasets have implications for
outcomes research conducted in pharmaceutical compa-
nies. There is little literature on the use of observational
data in economic evaluation, and more debate on this
subject is needed. As we gain a better understanding of
the tradeoffs between internal and external validity, it is
predicted that more pharmacoeconomic analyses will in-
creasingly be based on observational data or a combina-
tion of observational and RCT data.
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Data source
Observational RCT
Resource use consequences 21 27
Clinical events 19 37
Disease outcomes 19 33
All 3 sets of core data 9 14




Resource use consequences 3 20
Clinical events 6 9
Disease outcomes 6 13
All 3 sets of core data 1 6
OBJECTIVES: To evaluate the accuracy of claims versus
original prescriptions by calculating the match rate for 7
fields: drug, strength, dosage form, quantity, day’s sup-
ply, daily dose, and date dispensed. Claims accuracy was
also analyzed by therapeutic class for antibiotics, oral hy-
poglycemics, H2 antagonists, antipsychotics, and antide-
pressants. METHODS: Purdue’s Pharmaceutical Eco-
nomics Research Center (PERC) systematically recruited
10 pharmacies from a random list generated by phar-
macy benefits manager PCS Health Systems, Inc. (PCS).
PCS randomly extracted 500 claims submitted by each
pharmacy between 07/01/96 and 06/30/97. Pharmacies
obscured patient information and photocopied the origi-
nal prescriptions. Trained assistants abstracted 5 fields
and calculated day’s supply and daily dose from the di-
rections for use. RESULTS: Six of 10 pharmacies pro-
vided 2,938 photocopies, split approximately evenly
among therapeutic classes. Overall match rates were:
drug (99.9%), strength (97.0%), dosage form (95.5%),
quantity (94.1%), day’s supply (85.2%), daily dose
(83.2%), and date dispensed (65.1%). Applicable mean
percentage differences were: strength (1.32%), daily dose
(2.53%), day’s supply (2.73%), and quantity (6.03%).
The mean difference for date dispensed was 19.3 days.
Match rates were comparable for antidepressants, anti-
psychotics, and H2 antagonists. Antibiotic and oral hy-
poglycemic rates were more variable. CONCLUSIONS:
Claims reliability was excellent for drug, strength, dosage
form, and quantity and good for day’s supply and daily
dose. Antidepressant, antipsychotic, and H2 antagonist
classes had comparable reliability. The reliability of date
dispensed appeared questionable, but the dates recorded
by hand on prescriptions were later than those automati-
cally submitted for claims, suggesting that claims data
may be more accurate than the original prescriptions.
This study found prescription claims to be a reliable data
source for health care research.
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When conducting economic analyses using administra-
tive claims, it is important to account for the impact of
comorbidities on healthcare costs. The Chronic Disease
Score (CDS) is a useful risk-adjustment tool for use in
pharmacy claims-based research, however the published
version does not include important new drugs and the
weights were developed from smaller, geographically re-
stricted databases. OBJECTIVES: The purpose of this
study is to: (1) update the number and types of drugs in-
cluded in the CDS (2) develop new weights based on a
large, multi-region pharmacy claims database, and (3)
evaluate the revised CDS in explaining variations in and
predicting drug expenditures. METHODS: Analyses
